Anakinra is a recombinant IL-1 inhibitor that is currently FDA approved for rheumatoid arthritis, cryopyrin-associated Periodic Syndromes, and Deficiency of IL-1 Receptor Antagonist.IL-1β is a pro-inflammatory cytokine, and in conjunction with other pro-inflammatory cytokines and interferon, can trigger hyperinflammation and ARDS which is often seen in severe COVID19. Throughout the pandemic, Anakinra has been evaluated…
Related lists
Hospital Lists